[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606508":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":26,"locations":36,"responsibleParty":68,"collaborators":18,"id":71,"slug":18,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Anhui Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental:Neuronavigation-guided individualized intermittent theta burst stimulation (iTBS)","EXPERIMENTAL","Participants will receive iTBS daily for 2 week within real-world treatment settings",[13],"Other: Neuronavigation-guided individualized iTBS",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group: ordinary drug treatment","NO_INTERVENTION","The participants will receive regular medication treatment every day for 2 week.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Neuronavigation-guided individualized iTBS","Participants will receive individualized iTBS for 14 consecutive days in addition to their usual medication regimen.\n\niTBS parameters: 50 Hz bursts every 200 ms (5 Hz), 2s on\u002F8s off, total 600 pulses per session;6 sessions\u002Fday (3 in morning, 3 in afternoon, 3600 pulses\u002Fday); 100% RMT intensity; Neuronavigation: Brainsight system (Rogue Research, Canada)",[9],[25],"iTBS",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},"Kai Wang, MD","CONTACT","0551 6516 7581","wangkai1964@126.com",{"name":33,"role":29,"phone":34,"phoneExt":18,"email":35},"Gong-Jun Ji, PhD","+8618134516380","jigongjun@163.com",[37,54],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Hefei","Anhui","230000","China",{"type":44,"coordinates":45},"Point",[46,47],117.28083,31.86389,{"lat":47,"lon":46},[50],{"name":51,"role":29,"phone":52,"phoneExt":18,"email":53},"Gong-Jun Ji","+86-18134516380","2015500024@ahmu.edu.cn",{"facility":5,"status":55,"city":39,"state":40,"zip":56,"country":42,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"NOT_YET_RECRUITING","230032",{"type":44,"coordinates":58},[46,47],{"lat":47,"lon":46},[61,63,65],{"name":62,"role":29,"phone":30,"phoneExt":18,"email":31},"Kai Wang, PhD",{"name":64,"role":29,"phone":34,"phoneExt":18,"email":35},"Gong-Jun, PhD",{"name":66,"role":67,"phone":18,"phoneExt":18,"email":18},"Qiang Hua, PhD","PRINCIPAL_INVESTIGATOR",{"type":67,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"WANG KAI","Head of the Department, Department of Neurology, The First Affiliated Hospital of Anhui Medical University","100606508",false,"NCT07176468","Personalized iTBS in Real-World Clinical Settings for Schizophrenia","Efficacy of Personalized iTBS in Real-World Clinical Settings for Alleviating Schizophrenia Symptoms : A Randomized Single-Blind Trial","EPSREAL-SC","Inclusion Criteria:\n\n* Aged 18-60 years, any gender\n* Meets DSM-5 criteria for schizophrenia\n* Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days\n* Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments\n\nExclusion Criteria:\n\n* Active suicidal ideation or behavior\n* Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma)\n* Contraindications to MRI or TMS (e.g., metal implants, pacemakers)\n* Pregnancy or lactation\n* Receipt of TMS or ECT within the past 6 months\n* Judged by investigators to be unsuitable for participation","ALL","18 Years","60 Years",{"count":82,"type":83},40,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.\n\nThe main questions it seeks to address are:\n\nDoes the personalized iTBS target TMS protocol improve clinical symptoms in patients with schizophrenia within real-world treatment settings? What neural circuit changes, as assessed by functional MRI, occur following TMS treatment?\n\nParticipants will:\n\nUndergo personalized,personalized iTBS target treatment daily for 2 weeks. Complete baseline and post-treatment assessments, including clinical symptom scales (PANSS, HAMA, HAMD) and neuropsychological tests (MoCA, DST, VFT, Stroop Test, and AVLT).\n\nHave structural and resting-state functional MRI scans before and after treatment.\n\nBe monitored for any treatment-related adverse events.",[89,90],"Schizophrenia","Transcranial Magnetic Stimulation",[92,93,94],"schizophrenia","transcranial magnetic stimulation","Functional Magnetic Resonance Imaging (fMRI)","2025-12-28",{"date":97,"type":98},"2025-12-30","ACTUAL",{"date":100,"type":98},"2025-10-20",{"date":102,"type":83},"2026-09-20",{"name":5,"class":6},2]